Egetis Therapeutics AB
EGTX.STDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Mangafodipir
Chemotherapy
PledOx (2 µmol/kg)
Advanced Metastatic (Stage IV) Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mangafodipir | Phase 2 | Chemotherapy | - | - |
PledOx (2 µmol/kg) | Phase 2 | Advanced Metastatic (Stage IV) Colorectal Cancer | - | - |
Frequently asked questions
What is in Egetis Therapeutics AB's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Egetis Therapeutics AB's (EGTX.ST) pipeline across Phase 2. Its lead program is Mangafodipir (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Egetis Therapeutics AB's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Egetis Therapeutics AB (EGTX.ST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EGTX.ST biotech catalysts?→
Add EGTX.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Egetis Therapeutics AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.